Hirsch, Martin http://orcid.org/0000-0002-4496-1458
Immisch, Ilka
Knake, Susanne
Schulze-Bonhage, Andreas
Funding for this research was provided by:
BIAL
Universitätsklinikum Freiburg
Article History
Accepted: 18 October 2023
First Online: 3 November 2023
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. The study was funded by the pharmaceutical company BIAL.
: Martin Hirsch has received lecture fees or grants from Precisis, UCB, Angelini Pharma, Livanova, Eisai, BIAL and UNEEG. Ilka Immisch received lecture fees from Angelini Pharma and consulting fees from Precisis. Susanne Knake received lecture fees from Angelini Pharma, BIAL, Desitin, Epilog, Eisai, Merck Serono, Precisis AG, UCB and Zogenix. Andreas Schulze-Bonhage has received grants from BIAL, Precisis and UNEEG, and has received honoraria for lectures or advice from Angelini Pharma, BIAL, Desitin, Eisai, GW, UCB and UNEEG.
: The study was conducted at two sites, Freiburg Epilepsy Center and Marburg Epilepsy Center after approval of the local ethics committees.
: All patients gave informed consent prior to inclusion in the study.
: Not applicable.
: Data will be made available upon reasonable request.
: Not applicable.
: Martin Hirsch and Ilka Immisch contributed equally to the manuscript. They were involved in the conception and design of the study, collected and analyzed data, and drafted the manuscript. Andreas Schulze-Bonhage was involved in the conception of the study and provided expert guidance on the study design and data interpretation. He reviewed and edited the manuscript for intellectual content and approved the final version. Susanne Knake provided expert guidance on the study design and data interpretation, and critically reviewed the manuscript.